# BPL-003 Efficacy and Safety in Treatment Resistant Depression

> **NCT05870540** · PHASE2 · COMPLETED · sponsor: **Beckley Psytech Limited** · enrollment: 196 (actual)

## Conditions studied

- Treatment Resistant Depression

## Interventions

- **DRUG:** BPL-003
- **DRUG:** BPL-003

## Key facts

- **NCT ID:** NCT05870540
- **Lead sponsor:** Beckley Psytech Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-14
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-07-03
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05870540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05870540, "BPL-003 Efficacy and Safety in Treatment Resistant Depression". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05870540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*